Project 1 Project 2
Proteomic Approaches for Cancer Diagnostics
Dr. Zhong’s team focuses on early cancer detection using autoantibody profiles as biomarkers. They have developed novel screening technology for early detection of lung cancer using T7 phage display cDNA libraries and differential biopanning to isolate epitopes reacting with antibodies present specifically in the sera of patients with lung cancer. Using five combined biomarkers, they have achieved both sensitivity and specificity of 91.3 percent for stage I non-small cell lung cancer detection (Zhong, 2005), and sensitivity of 82.6 percent and specificity of 87.5 percent for detection of occult (one to five years prior to diagnosis) non-small cell lung cancer (Zhong, 2006). The goal is to use serum reactivity to proteins expressed in the tumors as diagnostic or prognostic biomarkers.
Zhong L, Hidalgo GE, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Protein Microarray as a Diagnostic Assay for Non-Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine. 2005 Nov;172:1308-14. PMID: 16109979
Zhong L, Coe S, Stromberg AJ, Khattar NH, Jett JR. Hirschowitz EA. Profiling Tumor-associated Autoantibodies for Early Stage Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 2006 Jul;1:513-9. PMID: 17409910